L&K Biomed엘앤케이바이오
156100 · KOSDAQ · ₩156100 · 엘앤케이바이오
₩6,270▼ ₩910 (12.67%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 83.4% | 82.6% | 83.8% | 86.2% | 75.3% | 48.5% |
| Operating margin | 1.3% | 1.8% | 8.5% | 6.8% | −66.1% | −100.2% |
| Net margin | 6.9% | −41.9% | 27.0% | −6.2% | −68.9% | −62.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +2.6% | +7.8% | +20.7% | +51.3% | +28.6% | — |
| Operating income growth | −27.4% | −76.8% | +51.3% | +115.6% | +15.2% | — |
| Net income growth | +117.0% | −267.3% | +621.8% | +86.3% | −41.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 5.1% | −37.0% | 25.0% | −7.8% | −74.2% | −39.5% |
| Return on assets | 2.2% | −20.2% | 12.6% | −9.1% | −29.0% | −23.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 94.0% | 116.1% | 130.5% | 105.2% | 389.4% | 139.2% |
| Net debt to equity | 9.2% | 26.1% | 6.7% | −5.3% | 146.9% | 16.9% |
| Current ratio | 189.1% | 159.6% | 162.7% | 195.1% | 95.2% | 301.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: L&K Biomed / 엘앤케이바이오 / 156100 / KRX:156100
Source: KRX statistical information